GlassScriptPhysician profile
Qiang Cai
NPI 1932112653
$14,230.12
in general payments reported to CMS, 2019-2025
30 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,150 · 2020: $770 · 2021: $725 · 2022: $1,680 · 2023: $1,859 · 2024: $1,430 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,906.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,434.94 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Boston Scientific Corporation | $824.00 | 2019-2025 | Exalt Model D, X-Tack Endoscopic Helix Tacking System, Orcapod |
| Janssen Biotech, INC. | $792.49 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $748.22 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $673.51 | 2021-2025 | Entyvio |
| Conmed Corporation | $608.35 | 2020 | |
| Gilead Sciences, INC. | $494.48 | 2022-2025 | Epclusa, Livdelzi |
| Erbe USA INC | $386.32 | 2020-2025 | Vio3 |
| Micro-Tech Endoscopy USA, INC. | $314.41 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $306.59 | 2022-2024 | Stelara |
| Genzyme Corporation | $290.93 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $235.15 | 2023-2025 | Dupixent |
| Daiichi Sankyo INC. | $180.16 | 2022-2023 | Injectafer |
| Endogastric Solutions, INC | $179.76 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $120.00 | 2019 | |
| Pfizer INC. | $85.12 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $83.35 | 2023-2025 | Terlivaz |
| Pentax of America, INC. | $69.02 | 2024 | Pentax Medical, C2 Cryoballoon Focal Controller, Inspira |
| Madrigal Pharmaceuticals | $65.84 | 2025 | Rezdiffra |
| Amgen INC. | $44.04 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $32.29 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $27.19 | 2024 | Voquezna |
| Creo Medical INC. | $26.80 | 2024 | Speedboat Ultraslim (Sb1l) |
| Celgene Corporation | $19.54 | 2022 | |
| Merck Sharp & Dohme LLC | $17.50 | 2022 | |
| Braintree Laboratories, INC. | $17.38 | 2021 | |
| Steris Corporation | $14.01 | 2023 | |
| Ferring Pharmaceuticals INC. | $13.73 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qiang Cai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.